The following data were presented at the American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals meeting in Chicago.
• 4SC AG, of Planegg-Martinsried, Germany, presented final results from its Phase IIb COMPONENT study that demonstrated substantial anti-inflammatory activity of vidofludimus in rheumatoid arthritis. The international, multicenter, randomized study evaluated the efficacy of vidofludimus in combination with methotrexate (MTX) compared with MTX alone.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST